OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
VSTM
Verastem, Inc.
There isn't enough reported data to score VSTM yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
VSTM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
VSTM's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
VSTM PE Valuation
VSTM has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
VSTM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect VSTM's losses to grow, with revenue growing.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 147% for OSCR versus VSTM down 151%.
VSTM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$3.90 | +$0.14 |
| Q2 2024 | -$4.05 | +$0.32 |
| Q1 2024 | -$5.11 | -$0.67 |
| Q4 2023 | -$4.81 | -$0.25 |
| Q3 2023 | -$4.04 | +$0.64 |
| Q2 2023 | -$4.37 | +$0.79 |
| Q1 2023 | -$4.44 | +$0.48 |
| Q4 2022 | -$4.56 | +$0.36 |
VSTM is still losing money, but far less than before: $2.00 per share over the past year, against $24.12 at its worst in late 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over VSTM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over VSTM on profitability, with a higher operating margin.
VSTM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24M | +114% |
| Q2 2026 | $40.1M | +1775% |
| Q2 2025 | $2.1M | -79% |
| Q1 2022 | $2.6M | +158% |
| Q4 2021 | $545K | +7.7% |
| Q3 2021 | $2K | -100% |
| Q2 2021 | $500K | -88% |
| Q1 2021 | $1M | -80% |
VSTM's revenue is recovering but still below its 2020 peak: $24M last quarter, up 114% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -313% | +49 points |
| Q2 2026 | -82% | +1966 points |
| Q1 2026 | -240% | N/A |
| Q4 2025 | -237% | N/A |
| Q3 2025 | -362% | N/A |
| Q2 2025 | -2048% | -1865 points |
| Q2 2024 | -183% | N/A |
| Q1 2022 | -654% | +748 points |
VSTM's operating margin was −313% last quarter, up 49 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
VSTM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2024 | -$23.8M | -$7.2M |
| Q1 2024 | -$28.3M | -$8M |
| Q4 2021 | -$9.9M | +$11.8M |
| Q3 2021 | -$10.8M | -124% |
| Q1 2021 | -$19.5M | +$14.5M |
| Q4 2020 | -$21.7M | +$15.5M |
VSTM has burned cash in almost every quarter: −$155M over the past year, against −$89M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over VSTM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
VSTM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +1.1M shares |
| 1 year | +37% | +27.2M shares |
| 3 years | +505% | +84.5M shares |
| 5 years | +615% | +87.1M shares |
| Available history | +1492% | +94.9M shares |
VSTM has 101M diluted shares, up 37% from a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
VSTM Net Leverage
VSTM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
VSTM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.0 | Neutral |
| Stochastic | 67.9 | Neutral |
VSTM's weekly RSI is 58 (neutral) and its Stochastic is 68 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
VSTM PE vs Healthcare Sector
VSTM has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over VSTM on trend strength, trading above more of its moving averages.
VSTM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.64 | 2.3% below |
| 20 week MA | $7.37 | 15% above |
| 50 week MA | $6.54 | 29% above |
| 100 week MA | $6.76 | 25% above |
| 200 week MA | $6.95 | 21% above |
VSTM has slipped below its 8-week average, but it's still above the other four, and 21% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over VSTM on returns for 2026, with the stronger performance.
VSTM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.8 | $27.6 | +64% |
| 2021 | $27.6 | $27.7 | +0.4% |
| 2022 | $27.7 | $4.08 | -85% |
| 2023 | $4.08 | $8.14 | +100% |
| 2024 | $8.14 | $3.71 | -54% |
| 2025 | $3.71 | $8.06 | +117% |
| 2026 YTD | $8.06 | $8.44 | +4.7% |
VSTM's yearly returns have swung widely, from +117% in 2025 to −85% in 2022. It's up 4.7% so far in 2026.